Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Study evaluates the drug-drug interaction between Ticagrelor and Venlafaxine when taken together in healthy volunteers
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ticagrelor | Drug | 90 mg oral immediate release tablets, single dose on days 1 and 9 | ||
| Venlaflaxin | Drug | 37.5 mg oral immediate release tablets, administered twice daily on days 4-8 |
| Measure | Description | Time Frame |
|---|---|---|
| area under the plasma concentration-time curve during a dosing interval (AUCÏ„) and observed maximum plasma concentration (Cmax) | Venlafaxine and O-desmethylvenlafaxine (ODV) on Day 8 (after multiple dose administration of venlafaxine for 4 days) and Day 9 (after concomitant administration of venlafaxine and ticagrelor): | Multiple assessments during day 8 and 9. |
| Measure | Description | Time Frame |
|---|---|---|
| Venlafaxine and ODV on Days 8 and 9: time to Cmax (tmax) | Ticagrelor and AR-C124910XX on Day 1 (after single dose administration of ticagrelor) and Day 9 (after concomitant administration of venlafaxine and ticagrelor): area under the plasma concentration-time curve from zero to infinity (AUC), Cmax, tmax and apparent terminal half-life t½λz | Multiple assessments during day 1 and 9-11 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jay Horrow, PhD | AstraZeneca Wilmington | Study Director |
| Mirjana Kujacic, PhD | AstraZeneca Mölndal | Study Chair |
| Kelli Craven, MD | Quintiles Kansas Overland Park US | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Overland Park | Kansas | United States | |||
| Research Site |
Not provided
| ID | Term |
|---|---|
| D000077486 | Ticagrelor |
| ID | Term |
|---|---|
| D000241 | Adenosine |
| D011684 | Purine Nucleosides |
| D011687 | Purines |
| D006574 | Heterocyclic Compounds, 2-Ring |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Safety and tolerability of ticagrelor and venlafaxine when given concomitantly by assessments of amount of adverse events | Multiple assessments from day -1 do day 12 and a single assessment at follow up visit. |
| Uppsala |
| Sweden |
| D000072471 |
| Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D009705 | Nucleosides |
| D009706 | Nucleic Acids, Nucleotides, and Nucleosides |
| D012263 | Ribonucleosides |